Sponsors, researchers and Institutional Review Boards (IRBs) are often wary about payments in research participation, citing concerns about coercion and undue influence, whether real or perceived, and have avoided payments that are “too high.” New research on how people make decisions about research participation, and new approaches to this question, bring a new perspective; are payments to participants actually too low? This paper explores this question, and whether we should, in fact, worry much less about restricting compensation for research participants.Enter content here
Most Recent Flipbooks
Save the Data. Protect the Patients. Prepare for What Comes Next: Remote Clinical Research Coordinators
Clinical Research Trends & Insights for 2020
16 industry experts share shifts and trends that will inform clinical research in 2020 and beyond.

Advances in Oncology Extend Lives, but Lead to New Safety Considerations for Sponsors and Investigators
From cardiovascular adverse events to complex dosing regimens, oncology trials present unique safety-related considerations.

The Most Important Voice Is Missing: The Case For Including Patient Insights In Protocol Design

Something Has to Give: The Current Unsustainable Approach to Safety Reporting Puts Trials and Patients at Risk
Something Has to Give: The Current Unsustainable Approach to Safety Reporting Puts Trials and Patients at Risk

Part 12: Public Awareness of Clinical Research and the Path to Diversity in Clinical Trials

Part 10: Unique Challenges and Opportunities for Emerging Biopharma Companies with Focused Pipelines

Part 6: Going Remote During COVID-19: Considerations When Moving Studies Out of the Clinic Setting